From the 1918 influenza pandemic to COVID-19, severe respiratory infections have shown why rapid diagnosis must connect with treatment. BioRadar® brings that connection to life through Diagno‑Care: broad pathogen detection and quantitative monitoring that guide treatment decisions.
2.5M estimated annual pneumonia deaths
38% of adults had a pathogen identified in the cited hospitalized-pneumonia study
48h+ for many culture results
Sources: Global Burden of Disease study (via Every Breath Counts, 2023); Jain et al., N Engl J Med 2015 (EPIC study, US).
Better information throughout treatment
BioRadar® identifies pathogens and measures how their levels change over time. Diagno‑Care connects those results with treatment decisions, from understanding the infection to monitoring its response.
See the infection more clearly. Detect multiple pathogens in one test.
Track what changes. Measure pathogen levels over time.
Guide treatment decisions. Use quantitative results to inform ongoing care.
Which pathogens are present? Broad detection across the pneumonia panel.
How much is present? Quantitative pathogen measurements.
What changes during treatment? Repeat measurements that track pathogen levels.
How quickly are results available? Approximately two hours from sample to report.
One platform. Six advantages for better care.
Broad pathogen detection
Rapid actionable results
Simple cartridge workflow
Quality controls throughout
Quantitative treatment monitoring
AI-powered analysis
BioRadar® for outbreak surveillance
Our vision is a connected BioRadar® network that reveals pathogen patterns across locations and helps public-health teams identify and treat emerging threats.